Paracodine

Active Ingredient:: Dihydrocodeine Tartrate
Origin:: EU

Paracodine (Dihydrocodeine Tartrate)

International sale not permitted. Listed for the domestic market and B2B only.

Dihydrocodeine tartrate, the active ingredient in Paracodine, is an opioid analgesic presented as a strength/form for oral use. It is used to manage moderate to severe pain in adult patients when other analgesics are insufficient.

GNH India supplies Paracodine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Teofarma S.R.L.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Paracodine is an opioid that acts on the central nervous system to relieve pain in several clinical contexts.

Moderate to severe acute pain: provides analgesia when non‑opioid analgesics are inadequate.
Chronic cancer‑related pain: helps control persistent pain associated with malignant disease.
Post‑operative pain: reduces pain intensity after surgical procedures.

How It Works

Dihydrocodeine tartrate binds to μ‑opioid receptors in the central nervous system, mimicking endogenous opioids. This binding inhibits the release of excitatory neurotransmitters, decreasing neuronal excitability and altering pain perception, which results in analgesic effects.

Side Effects

Adverse reactions to dihydrocodeine may vary in frequency and severity.

Common Side Effects

Nausea: mild to moderate upset stomach.
Constipation: reduced bowel motility.
Drowsiness: increased sleepiness or fatigue.
Dizziness: light‑headed feeling.
Dry mouth: reduced salivation.
Itching: mild skin pruritus.

Serious or Rare Side Effects

Respiratory depression: slowed or shallow breathing.
Severe allergic reaction: rash, swelling, or anaphylaxis.
Dependence or withdrawal: signs of opioid use disorder.
Low blood pressure: hypotension causing faintness.
Hallucinations: visual or auditory disturbances.
Seizures: convulsive episodes.

Precautions & Warnings

When prescribing Paracodine, clinicians should consider several safety aspects.

Assess pain severity: ensure opioid therapy is appropriate for the level of pain.
Review medical history: check for respiratory disorders, liver disease, or substance‑use disorder.
Monitor for sedation: advise patients not to operate machinery while drowsy.
Avoid concurrent CNS depressants: limit use with alcohol or benzodiazepines.
Pregnancy and lactation: use only if benefits outweigh risks.
Store at ambient temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Dihydrocodeine may interact with a range of medicines, requiring vigilance.

Major Interactions (Avoid)

Other opioids: combined use can cause profound respiratory depression.
Benzodiazepines: additive central nervous system depression.
MAO inhibitors: risk of severe hypertension or serotonin syndrome.

Moderate Interactions (Monitor Closely)

Antihistamines: may increase drowsiness.
Antidepressants (SSRIs/SNRIs): potential for serotonin syndrome.
CYP3A4 inhibitors (e.g., erythromycin): may raise dihydrocodeylin levels.
Alcohol: enhances sedative effects and respiratory risk.

Frequently Asked Questions

Paracodine contains dihydrocodeine tartrate, an opioid analgesic used to treat moderate to severe pain, including acute postoperative pain, cancer‑related pain, and other situations where non‑opioid analgesics are insufficient.

Dihydrocodeine binds to μ‑opioid receptors in the brain and spinal cord, mimicking natural endorphins. This interaction reduces the release of pain‑transmitting neurotransmitters, decreasing neuronal excitability and altering the perception of pain.

The appropriate dose of Paracodine is determined by a qualified prescriber based on the patient’s pain severity, previous opioid exposure, age, weight, and overall health status. Dosage instructions are provided on the prescription label.

Paracodine should be used during pregnancy or lactation only if the potential benefit justifies the potential risk to the fetus or infant. Opioids can cross the placenta and may be present in breast milk, so clinicians weigh risks carefully.

To order Paracodine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any required import documentation.

Paracodine (dihydrocodeine) is a semi‑synthetic opioid that offers analgesic potency between codeine and morphine. Compared with stronger opioids like morphine, it has a lower risk of severe respiratory depression but still requires careful monitoring for dependence and side effects.

Paracodine should be stored at ambient temperature, below 25 °C, in its original container, protected from moisture, heat, and direct light. Keep out of reach of children and do not use if the packaging is damaged.

Paracodine is administered orally, typically as a tablet or liquid formulation, and should be taken exactly as prescribed. Swallow tablets whole with water; do not crush or chew unless specifically instructed by a healthcare professional.

Serious risks include respiratory depression, severe allergic reactions, opioid dependence, and overdose. Patients should be educated on recognizing signs of respiratory compromise and instructed to seek immediate medical attention if symptoms occur.

Paracodine is contraindicated in individuals with known hypersensitivity to dihydrocodeine or other opioids, those with severe respiratory depression, acute or severe asthma, and patients who have taken MAO inhibitors within the past 14 days.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 15 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.